Hanmi licenses sonefpeglutide to Lilly
Analysis based on 11 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The market is positively impacted by this licensing agreement, particularly for Hanmi Pharm due to the significant upfront payment and potential milestone payments, which will boost its financial position and validate its LAPSCOVERY platform. Eli Lilly and Company's stock may see a positive reaction as it expands its drug pipeline with a promising candidate, potentially leading to future revenue growth.
Hanmi Pharm has entered into a licensing agreement with Eli Lilly and Company for its biologic drug candidate, sonefpeglutide (GLP-2 analog). Under the agreement, Eli Lilly and Company gains exclusive worldwide rights, excluding South Korea, to develop, manufacture, and commercialize sonefpeglutide. Hanmi Pharm will receive an upfront payment of USD 75 million and is eligible for up to an additional USD 1.185 billion in clinical development, regulatory approval, and commercialization milestone payments, along with royalties on product launch. Hanmi Pharm will continue the ongoing global Phase 2 clinical trial for sonefpeglutide in short bowel syndrome (SBS), while Eli Lilly and Company will explore additional clinical trials. This deal highlights the potential of Hanmi Pharm's LAPSCOVERY™ long-acting platform technology.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard